Investing.com - United Therapeutics (NASDAQ: UTHR) reported second quarter EPS of $5.85, $0.63 worse than the analyst estimate of $6.48. Revenue for the quarter came in at $714.9M versus the consensus estimate of $689.93M.
United Therapeutics's stock price closed at $337.54. It is up 28.64% in the last 3 months and up 40.57% in the last 12 months.
United Therapeutics saw 3 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See United Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, United Therapeutics's Financial Health score is "excellent performance".
Check out United Therapeutics's recent earnings performance, and United Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar